Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF V600E mutations and respond to RAF inhibitors. However, detection of mutations in tissue biopsies is particularly challenging in histiocytoses due to low tumor content and stromal contamination. We applied a droplet-digital PCR assay for quantitative detection of the BRAF V600E mutation in plasma and urine cell-free (cf) DNA and performed a prospective, blinded study in 30 patients with ECD/LCH. There was 100% concordance between tissue and urinary cfDNA genotype in treatment-naïve samples. cfDNA analysis facilitated identifi cation of previously undescribed KRAS
INTRODUCTION
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are heterogeneous systemic histiocytic disorders characterized by accumulation and infi ltration of histiocytes in multiple tissues of the body, leading to organ compromise ( 1 ) . Although the underlying etiology of these conditions has long been enigmatic, recent investigations have determined that both LCH and ECD are clonal disorders of myeloid-derived precursor cells ( 2, 3 ) with a high frequency of somatic BRAF V600E mutations (40%-60% of patients; refs. 4-7 ). Moreover, treatment of patients with BRAF -mutant LCH and ECD with the BRAF inhibitor vemurafenib has demonstrated dramatic effi cacy, revolutionizing the care of these orphan diseases ( 8, 9 ) .
The above data underline the importance of accurately identifying BRAF mutational status in patients with systemic LCH and ECD ( 10, 11 ) . Unfortunately, the scant histiocyte content and marked stromal contamination that are a hallmark of these disorders make mutation detection in tissue biopsies challenging ( 3 , 10 ) . Moreover, the propensity of histiocytic lesions to involve diffi cult-to-biopsy locations such as the brain, orbits, and right atrium frequently necessitates the use of bone biopsies, further limiting the availability of suitable tumor material for BRAF genotyping ( 10, 11 ) . Finally, the infi ltrative and multifocal nature of these diseases, as well as the absence of a reliable tumor marker, has made evaluation of treatment response challenging.
Given these factors, the use of circulating tumor cellfree DNA (cfDNA) to both identify the BRAF V600E mutation and monitor response to therapy represents a potentially transformative development for these orphan diseases. A recent pilot study of 6 patients with ECD demonstrated that BRAF V600E mutations could be detected in cfDNA ( 12 ) . However, the concordance of cfDNA BRAF mutational genotype with tissue mutational status is not established in ECD and has never been evaluated in LCH. Moreover, the ability of quantitative cfDNA analysis to detect dynamic changes in BRAF V600E mutation burden during treatment of disease has not been studied. Finally, the use of urine as a source of cfDNA for mutational detection has previously been limited to malignancies of the genitourinary tract and offers signifi cant advantages in sample stability and ease of serial collection.
To evaluate the validity and clinical utility of plasma and urine cfDNA BRAF testing in patients with LCH and ECD, we performed the fi rst-of-a-kind blinded, prospective multicenter study in these disorders.
RESULTS

Cross-Sectional Analysis
Data from 30 patients (25 ECD and 5 LCH) were analyzed. Patient and sample characteristics are shown in Table 1 . Of these 30 patients, initial tissue BRAF V600E genotyping identifi ed 15 patients as mutant, 6 patients as wild-type, and 9 as indeterminate. Bone represented the most common anatomic site of attempted tissue acquisition, accounting for 36.7% of biopsies in this cohort ( Table 1 ) .
Urinary cfDNA analysis for detection of the BRAF V600E mutation was performed on all patients, and concordance between cfDNA and tissue DNA mutational results was analyzed. There was 100% concordance between tissue and urinary cfDNA genotype in samples from treatment-naïve patients. Urinary BRAF V600E cfDNA values obtained from any time point in therapy identifi ed 16 patients as mutant and 14 as wild-type (kappa = 0.88; 95% CI, 0.66-1.0; Supplementary Table S1 ). This resulted in a sensitivity of urinary cfDNA BRAF V600E detection of 92.9%, a specifi city of 100%, a positive predictive value of 100%, and a negative predictive value of 85.7% (all compared to BRAF V600E detection from 
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disease burden, whereas the tissue genotyping was performed before treatment. When considering only urinary or plasma samples obtained from treatment-naïve patients, there was a 100% concordance between tissue and urinary cfDNA genotype from urine and plasma ( Supplementary Fig. S1A and B) .
Plasma cfDNA and urinary cfDNA were obtained at the same time point in 19 of 30 (63.3%) patients. Results from plasma cfDNA for identifying the BRAF V600E mutation were comparable to urinary cfDNA results (Supplementary Table  S2 and Supplementary Fig. S1 ). Plasma cfDNA analysis identifi ed 9 patients as mutant and 10 as wild-type. BRAF genotype as determined by a urinary and plasma cfDNA assay was concordant for all samples from the 19 patients with both tests ( n = 26 tests), except one (which was obtained from a patient during RAF inhibitor therapy; 96% concordance). The quantitative BRAF V600E mutant: BRAF wild-type ratio was signifi cantly higher in the cfDNA from plasma as well as urine in those patients whose tissue was BRAF V600E versus wild-type ( P = 0.0005 and 0.002, respectively; Fig. 1B and C ).
Longitudinal Assessment of BRAF
V600E cfDNA Burden
Comparing cfDNA BRAF V600E : BRAF wild-type ratios of pretreatment versus BRAF inhibitor-treated BRAF V600E -mutant patients, a signifi cant decrease in the BRAF V600E : BRAF wildtype ratio was seen with therapy ( P < 0.0001; Fig. 2A ). Serial samples on 13 BRAF V600E -mutant patients were available, 10 of whom were treated with a BRAF inhibitor. In all patients treated with a BRAF inhibitor, serial urinary cfDNA analysis revealed progressive decrements in the BRAF V600E allele burden ( Fig. 2B ). Weekly serial urinary cfDNA analysis throughout the course of BRAF inhibitor therapy revealed that the decline in mutant cfDNA burden in response to BRAF inhibitors was consistent with radiographic disease improvement ( Fig. 3A and B ) .
Serial cfDNA BRAF V600E burden was also assessed in two patients treated with anakinra, an IL1 receptor antagonist commonly used as an off-label treatment for ECD ( 13 ) . Interestingly, treatment with anakinra also reduced the BRAF V600E -mutant allele burden ( Fig. 3C ) . Anakinra was subsequently discontinued in one patient, and within 7 days the urinary cfDNA BRAF V600E allele burden increased. Vemurafenib was then initiated in this patient, and once again BRAF V600E allele burden as assessed in cfDNA decreased within 2 weeks of BRAF inhibitor therapy.
In at least one patient for whom successful RAF inhibitor therapy was discontinued due to toxicity, urinary cfDNA BRAF V600E burden increased after vemurafenib discontinuation, which mirrored radiographic evidence of disease recurrence ( Fig. 3D ) .
Identifi cation of a KRAS Mutation in a BRAF
V600E
Wild-Type Patient
Of the patients enrolled in this study, 56.7% (17 of 30) were identifi ed as having a BRAF V600E mutation based on either tissue genotyping and/or cfDNA analysis. In addition to prevalent BRAF V600E mutations in these diseases, recurrent RAS mutations have also been recently identifi ed in ECD ( 14 ) , and therefore a noninvasive method of diagnosing somatic mutations in patients with BRAF wild-type ECD is of potential value. One BRAF wild-type patient here was found to have a KRAS G12S mutation in tissue material taken from a cardiac ECD lesion ( Supplementary Fig. S2A-D) . This mutation was also found to be present by cfDNA analysis in both plasma and urine ( Supplementary Fig. S2E and Supplementary Table   S3 ). Although NRAS mutations have been reported in ECD ( 15 ) , KRAS mutations have never previously been reported in these disorders.
DISCUSSION
This study demonstrates the utility of circulating cfDNA for reliably detecting actionable alterations and monitoring response to therapy in patients with histiocytic disorders. We identifi ed a high correlation of tissue mutational genotype with urine and plasma cfDNA mutational status, establishing the utility of cfDNA assessment of BRAF V600E mutations in patients with LCH and ECD. Moreover, quantitative BRAF V600E cfDNA allele burden changed dynamically with therapy and mirrored radiographic evaluation of disease. These fi ndings have potentially important implications for the initial diagnostic workup and serial monitoring of these rare disorders.
We found that 30% of patients (9 of 30) had an indeterminate BRAF mutation result from tumor tissue despite concerted genotyping efforts. This high proportion of patients with unknown tissue biopsy genotype underscores the substantial diffi culty in identifying tumor genotype information in patients with histiocytic disorders. The high proportion of BRAF genotyping test failures here likely relates to the frequent use of bone as a site of biopsy in these disorders. Eight of the 9 (88.9%) patients with an initial unknown BRAF tissue genotyping status had biopsies from bone. The molecular assessment of bony lesions is challenging, as morphologic assessment requires decalcifi cation procedures that often render the tissue unsuitable for molecular testing. Furthermore, aspirates of these lesions often yield suboptimal material for testing, with fi ndings of nonspecifi c infl ammation and/or fi brosis and low histiocyte content. Of the 9 patients with indeterminate BRAF genotype from tissue biopsy, cfDNA testing identifi ed BRAF mutations in 2 patients. These results have immediate therapeutic implications.
In addition to the use of cfDNA for establishing the initial presence or absence of BRAF V600E mutations, serial measurements of BRAF V600E -mutant allele burden on a variety of therapies revealed the utility of cfDNA analysis for dynamically monitoring response to both immunomodulatory and BRAF inhibitor therapy in these disorders. Assessment of treatment response has been an obstacle in the treatment of adult patients with histiocytic disorders, as radiographic assessments of response do not accurately characterize the wide spectrum of anatomic sites and lesion types characteristic of these disorders. Moreover, no formal criteria for the assessment of treatment response exist for adult patients with LCH and ECD ( 10 ) . Thus, these data support incorporation of urinary and/or plasma cfDNA allele burden as a potential surrogate marker for clinical benefi t in future clinical trials and standard of care for patients with histiocytic disorder. It is important to note that the rate of decline in the BRAFmutant allele burden in urinary and plasma cfDNA was variable between patients, underlining the need for multiple serial assessments of allele burden following initiation of therapy. Also, given that quantitative cfDNA BRAF V600E mutation detection mirrored response to multiple therapeutic modalities, it is likely that cfDNA detection of BRAF mutations will serve as a good marker of disease burden not only in response to RAF targeted therapy but also across a range of therapeutic agents commonly utilized in these disorders.
The use of urine as the source of cfDNA as reported here particularly facilitated routine serial monitoring of BRAF V600E allele burden. Although somatic mutation detection has previously been performed in the cfDNA of patients with cancer, nearly all prior studies utilizing urinary cfDNA in cancer were restricted to patients with genitourinary malignancies (16) (17) (18) . However, urinary cfDNA detection of BRAF V600E mutations mirrored closely the results from plasma cfDNA analysis here. Moreover, as shown in Fig. 3 , urinary samples for cfDNA could be obtained on a weekly basis, allowing for disease monitoring on an outpatient basis without the need for phlebotomy or other medical procedures. Previous studies indicate that DNA in urine can be stabilized for at least 9 days ( 18 ), whereas plasma requires processing within 6 hours for accurate assessment of cfDNA ( 19 ) .
The combined use of tissue and cfDNA genotyping analyses also allowed us to identify a KRAS mutation in a BRAF wildtype ECD patient (a mutation not previously described in ECD). Future interrogation of RAS mutations in tumor biopsies and cfDNA from patients with BRAF wild-type histiocytic disorders may provide an additional somatic mutational biomarker and therapy options in this patient population.
Overall, these data suggest that monitoring of BRAF V600E mutations in the cfDNA of patients with histiocytic disorders provides a reliable and convenient noninvasive method to detect BRAF V600E mutations and assess treatment response in these unique disorders.
METHODS
Patients
Between January 2013 and June 2014, 30 consecutive patients with LCH and ECD seen at the Memorial Sloan Kettering Cancer Center (MSKCC) and The MD Anderson Cancer Center (MDACC) were enrolled in the study.
Tissue biopsies were performed as part of routine clinical care, with the site of biopsy based on radiographic and/or clinical assessment of disease involvement. Ten milliliters of blood and between 60 and 120 mL of urine were collected at each time point. Plasma was separated from blood samples using standard techniques. All samples were deidentifi ed, and operators performing plasma and urine cfDNA analyses were blinded to the tissue genotype and clinical characteristics of all patients.
Institutional review boards at both MSKCC and MDACC approved the study protocol.
Of note, 6 plasma and 6 urinary cfDNA values that were previously reported in a pilot proof-of-concept study ( 12 ) were not included in the current study or data analysis.
Tissue Mutational Genotyping
Initial BRAF tissue mutation testing was performed by a variety of methods as part of routine care in Clinical Laboratory Improvements Amendments (CLIA)-certifi ed molecular diagnostic laboratories at MSKCC, MDACC, or the institution from which the patient was initially referred. Tissue with a BRAF V600E mutation identifi ed as part of these analyses was considered positive. For tissue to be considered negative for the BRAF V600E mutation for the purposes of this analysis, it was required to undergo further testing by a high-sensitivity assay, either Sanger sequencing with locked nuclear acid (LNA) clamping or next-generation sequencing. Sequencing with LNA was performed according to previously published procedures ( 20 ) and had a limit of detection of 0.5% mutant alleles. Massively parallel sequencing was performed by Foundation Medicine, Inc., using previously published methodologies ( 21 ) , with a minimum coverage of ×500. In patients for whom initial diagnostic tissue was insuffi cient for genotyping, additional biopsies were attempted as deemed appropriate by the treating physician. Patients were considered tumor BRAF indeterminate if they met one of the following criteria: (i) inadequate tumor material for genotyping despite multiple biopsy attempts, (ii) declined repeated biopsy for the purpose of genotyping, and (iii) tissue genotyping was ordered but no result was obtained due to failure of the tumor material to meet technical requirements. 
Plasma and Urine cfDNA Extraction and Analyses
Plasma cfDNA was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. Urine cfDNA was isolated as previously described ( 12 ) .
Urine and plasma cfDNA were quantifi ed by a droplet-digital PCR (ddPCR; QX-100, BioRad) assay to a 44-bp amplicon of RNase P, a single-copy gene, as previously described ( 12 ) . Quantifi ed DNA up to 60 ng was used for mutation detection of BRAF V600E by ddPCR and KRAS mutations at codons 12 and 13 of exon 2 by massively parallel sequencing.
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For BRAF V600E mutation detection, a two-step PCR assay targeting a very short (31 bp) amplicon was employed to enhance detection of rare mutant alleles in cfDNA. The fi rst-step amplifi cation was done with two primers fl anking the BRAF V600E locus, where both primers contain noncomplementary 5′ tags that hybridize to second-round primers. A complementary blocking oligonucleotide suppressed wild-type BRAF amplifi cation, achieving enrichment of the mutant BRAF V600E sequence in this step. The second step entailed a duplex ddPCR reaction using FAM ( BRAF
V600E
) and VIC (wild-type BRAF ) TaqMan probes to enable differentiation of mutant versus wild-type quantifi cation, respectively. The RainDrop ddPCR platform (RainDance) was used for PCR droplet separation, fl uorescent reading, and counting droplets containing mutant sequence, wild-type sequence, or unreacted probe.
For each patient sample, the assay identifi ed BRAF V600E mutation fragments detected as a percentage of detected wild-type BRAF . As previously published, thresholds for the BRAF assay were initially developed by evaluating a training set of urinary cfDNA from patients with BRAF V600E metastatic cancer (positives) and healthy volunteers (negatives) using a classifi cation tree that maximized the true-positive and true-negative rates ( 12 , 22 ) . Using this training set, a double threshold approach with an indeterminate range between not detected and detected was estimated, yielding two threshold values (<0.05 not detected; 0.05-0.107 indeterminate; >0.107 detected; ref. 12 ). For this current study, however, the assay was simplifi ed to a dichotomous classifi er by combining both indeterminate and negative ranges as "not detected," yielding a single cutoff of ≤0.107 for not detected and >0.107 for detected. A single cutoff point was preselected to evaluate the performance of this assay within this cohort for false-positive and false-negative rates for the detection of BRAF
(this was chosen because defi nitions of sensitivity and specifi city are not compatible with a classifi er containing an indeterminate range).
For plasma detection, wild-type BRAF patients with metastatic cancer (13 plasma samples) were used to determine a threshold for detection of BRAF V600E mutations. The BRAF V600E values for this wild-type BRAF population were normally distributed, and therefore a cutoff point equivalent to 3 SDs (0.021%) above the mean of wildtype BRAF controls (0.031%) or >0.094% mutant to wild-type was considered positive for BRAF V600E ( 12 ) . For KRAS mutation detection (G12A/C/D/R/S/V, G13D), a twostep PCR assay similar to that described for BRAF V600E was employed with an initial 31-bp targeted region, except that during the second round, fl anking primers were used to add patient-specifi c barcodes and adaptor sequences necessary for massively parallel DNA sequencing per manufacturer's instructions (MiSeq; Illumina). Sequence reads were fi ltered for quality ( Q score > 20) and verifi ed as matching the target sequence (no more than 3 mismatches permitted outside the mutation region). For each sample, KRAS -mutant sequences were tallied and the percentage of mutant was computed. For the KRAS assay, the distribution of background signal in the wild-type population was observed not to conform to a normal distribution. To be consistent with the plasma BRAF assay approach for computing the threshold (mean + 3 SD), the median and median absolute deviation of a KRAS wild-type population was used to produce a "robust" z -score, and a cutoff of greater than 4 z -scores above the median mutant signal count of the population (or >0.02%) was determined to be a positive result ( 23 ) . This approach is approximately equal to the mean + 3 SD threshold when the data are normally distributed (data not shown).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism V5.0 for Macintosh (GraphPad Prism Software). The Mann-Whitney U test was used to compare BRAF V600E mutant: BRAF wild-type ratios determined by cfDNA analysis in patients identifi ed as BRAF wild-type based on tissue biopsy versus those identifi ed as BRAF V600E mutant based on tissue biopsy. In addition, the Mann-Whitney U test was also used to compare BRAF V600E mutant: BRAF wild-type ratios obtained from urinary cfDNA pretreatment with vemurafenib versus urinary cfDNA BRAF V600E mutant: BRAF wild-type ratios obtained following initiation of therapy with vemurafenib. Concordance of tissue, plasma, and urinary assessment of BRAF V600E mutational detection was performed by calculating the kappa coeffi cient. A two-tailed P value of <0.05 was considered statistically signifi cant.
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